Goldman Sachs’s Adverum Biotechnologies ADVM Stock Holding History

Goldman Sachs’s Portfolio ADVM Stock Details ADVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-20,000	Closed	-$1.03M	–	7003
2016 Q1	$1.03M	Hold	20,000	–	–	﹤0.01%	4047
2015 Q4	$1.9M	Buy	20,000 +16,400	+456%	+$1.44M	﹤0.01%	3681
2015 Q3	$297K	Sell	3,600 -21,150	-85%	-$2.7M	﹤0.01%	5615
2015 Q2	$4.02M	Buy	+24,750	New	+$8.35M	﹤0.01%	3157

Goldman Sachs's ADVM Position: Q4 2025 in Review

Goldman Sachs sold out of Adverum Biotechnologies (ADVM) in Q4 2025, closing a stake of 402,581 shares — an estimated $1.82M sold.

Goldman Sachs first reported a position in ADVM in Q3 2014 and held it in 39 quarters. The position peaked at $23.8M in Q2 2020. 0 funds tracked by Wall St. Rank hold ADVM as of Q4 2025.

Goldman Sachs reported no remaining Adverum Biotechnologies position as of Q4 2025 after selling out during the quarter.
Goldman Sachs sold 402,581 Adverum Biotechnologies shares in Q4 2025, an estimated $1.82M.
Goldman Sachs first reported a position in Adverum Biotechnologies in Q3 2014 and held it in 39 quarters.
Goldman Sachs's Adverum Biotechnologies position peaked at $23.8M in Q2 2020.
0 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q4 2025.

Based on Goldman Sachs's 13F filing for Q4 2025, filed 10 Feb 2026.